SGGW and UW conduct research on early diagnosis of Parkinson’s and Alzheimer’s diseases
Dr hab. Ryszard Kozera prof. SGGW, mgr inż. Aleksandra Konopka, and mgr inż. Karol Struniawski affiliated with the Institute of Information Technology, SGGW, in cooperation with dr inż. Piotr Hańczyc from the Division of Optics, Faculty of Physics, University of Warsaw, work on early detection technology for neurodegenerative disorders.
The project aims to develop technology for early detection of neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases. The innovativeness of the developing method is based on the spectral analysis of the patient’s samples. The test can identify the presence of amyloids associated with those diseases. The research process involves fluorescent labelling with medical dyes that bind to amyloids and laser scanning the biological material. This allows them to precisely determine the amount of harmful proteins in the patient’s material.
The team of researchers from the Institute of Information Technology, SGGW, dr hab. Ryszard Kozera prof. SGGW, mgr inż. Aleksandra Konopka i mgr inż. Karol Struniawski works on the automated research system. They focus on creating a solution to analyse protein samples obtained with a spectroscope for amyloid accumulation using image processing methods and AI. The researchers aim to develop a system that will automate obtaining and processing spectroscopic images, so that the created solution can be widely used, including in screening. The practitioner will receive the test result, including a recommendation prepared based on the test analysis using AI algorithms.
“The aim of our project is not only to reduce the time of analysis but also to facilitate the entire process of examining samples, which is expected to make it easier for doctors to act. Thus, it will be possible to use the developed technology in screening individuals who do not have symptoms of neurodegenerative disorders”, says mgr inż. Karol Struniawski, Institute of Information Technology, SGGW.
The transfer of cutting-edge technology is to be provided by Neurolight, a company founded by researchers from SGGW and UW. The early detection of neurodegenerative disorders will enable medicine to be more efficient in promoting patients’ healthcare, providing early intervention and preventing diseases from developing.
Consulted with mgr inż. Karol Struniawski